124 related articles for article (PubMed ID: 26291712)
21. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
22. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Roch N; Salameire D; Gressin R; Morand P; Epaulard O; Pavese P; Brion JP; Stahl JP
Scand J Infect Dis; 2008; 40(4):343-6. PubMed ID: 17934981
[TBL] [Abstract][Full Text] [Related]
23. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
Salles GA; Morschhauser F; Solal-Céligny P; Thieblemont C; Lamy T; Tilly H; Gyan E; Lei G; Wenger M; Wassner-Fritsch E; Cartron G
J Clin Oncol; 2013 Aug; 31(23):2920-6. PubMed ID: 23835715
[TBL] [Abstract][Full Text] [Related]
24. Obinutuzumab: a new class of anti-CD20 monoclonal antibody.
Gagez AL; Cartron G
Curr Opin Oncol; 2014 Sep; 26(5):484-91. PubMed ID: 25014645
[TBL] [Abstract][Full Text] [Related]
25. Rituximab-associated infections.
Gea-Banacloche JC
Semin Hematol; 2010 Apr; 47(2):187-98. PubMed ID: 20350666
[TBL] [Abstract][Full Text] [Related]
26. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
27. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.
Kang HJ; Park JS; Kim DW; Lee J; Jeong YJ; Choi SM; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
Respir Med; 2012 Mar; 106(3):443-50. PubMed ID: 22154502
[TBL] [Abstract][Full Text] [Related]
28. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
29. Cytomegalovirus meningoencephalitis after rituximab treatment for primary central nervous system lymphoma.
Siakantaris MP; Argyropoulos KV; Ioannou S; Papadopoulou V; Tzeletas G; Tsonis J; Dimitrakopoulou A; Yiannopoulou KG; Pangalis GA; Vaiopoulos G
Neurologist; 2015 Jan; 19(2):35-7. PubMed ID: 25607329
[TBL] [Abstract][Full Text] [Related]
30. A case of hypogammaglobulinemia with enteroviral meningoencephalitis, associated with increased adenosine deaminase in cerebrospinal fluid.
Alborizi A; Hosseini-nasab A; Zeyaeian M; Sanaei A; Kashef S
Iran J Allergy Asthma Immunol; 2009 Jun; 8(2):117-9. PubMed ID: 19671942
[TBL] [Abstract][Full Text] [Related]
31. Obinutuzumab for the treatment of lymphoproliferative disorders.
Owen C; Stewart DA
Expert Opin Biol Ther; 2012 Mar; 12(3):343-51. PubMed ID: 22283718
[TBL] [Abstract][Full Text] [Related]
32. [Enteroviral infection with acute hepatitis and its differential diagnosis from epidemic hepatitis].
Bliuger AF; Lishnevskiĭ MS
Sov Med; 1971 Oct; 34(10):111-6. PubMed ID: 5137119
[No Abstract] [Full Text] [Related]
33. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder.
Suzan F; Ammor M; Ribrag V
N Engl J Med; 2001 Sep; 345(13):1000. PubMed ID: 11575282
[No Abstract] [Full Text] [Related]
34. A case of enteroviral meningoencephalitis presenting as rapidly progressive dementia.
Valcour V; Haman A; Cornes S; Lawall C; Parsa AT; Glaser C; Yagi S; Tihan T; Bhatnagar J; Geschwind M;
Nat Clin Pract Neurol; 2008 Jul; 4(7):399-403. PubMed ID: 18477991
[TBL] [Abstract][Full Text] [Related]
35. Coxsackie B meningoencephalitis in a patient with acquired immunodeficiency syndrome and a multiple sclerosis-like illness.
Berger JR; Fee DB; Nelson P; Nuovo G
J Neurovirol; 2009 May; 15(3):282-7. PubMed ID: 19444695
[TBL] [Abstract][Full Text] [Related]
36. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
37. [Cryptococcus neoformans meningoencephalitis in a patient treated with rituximab].
Sánchez-Ojanguren J; Isern-Segura I; Chico-Chumillas C; Javaloyas-de-Morlius M
Med Clin (Barc); 2009 Jun; 133(4):157-8. PubMed ID: 19268330
[No Abstract] [Full Text] [Related]
38. [Clinical picture and differential diagnosis of serous meningitis and viral meningoencephalitis].
Gavura VV
Klin Med (Mosk); 1984 Jul; 62(7):22-8. PubMed ID: 6090766
[No Abstract] [Full Text] [Related]
39. Rapid detection of enteroviral RNA in cerebrospinal fluid (CSF) from patients with aseptic meningitis by reverse transcription-nested polymerase chain reaction.
Furione M; Zavattoni M; Gatti M; Percivalle E; Fioroni N; Gerna G
New Microbiol; 1998 Oct; 21(4):343-51. PubMed ID: 9812315
[TBL] [Abstract][Full Text] [Related]
40. Rituximab-induced hypersensitivity pneumonitis.
Tonelli AR; Lottenberg R; Allan RW; Sriram PS
Respiration; 2009; 78(2):225-9. PubMed ID: 18843175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
